“This quarter, with the BOND-003 monotherapy data presented at AUA, and the CORE-001 combination data presented at ASCO and subsequently published in Nature Medicine, we affirmed the potential for cretostimogene, our novel oncolytic immunotherapy candidate, to be used as a bladder-sparing backbone therapy for NMIBC,” said Arthur Kuan, Chairman & Chief Executive Officer of CG Oncology. “We demonstrated our commitment to bladder cancer patients by initiating our Expanded Access Program in June, and we’re encouraged by the strong enrollment that we’ve seen to date. Additionally, we strengthened our team across key functions to ensure that we have the optimal organizational structure for this stage of our growth. We look forward to sharing primary results from our BOND-003 registrational study of cretostimogene monotherapy later this year, and progressing toward submitting our Biologics License Application.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
- CG Oncology 4.068M share Block Trade priced at $33.90
- CG Oncology initiated with Buy on bladder cancer potential at BofA
- CG Oncology initiated with a Buy at BofA
- CG Oncology initiates EAP for Cretostimogene Grenadenorepvec in U.S.